Cancer patients get lifeline to keep taking promising drug
NCT ID NCT02955940
Summary
This study allows patients who were already taking the drug ruxolitinib in a previous cancer trial to continue receiving it, along with their other cancer treatments, if they are benefiting. It's for people with pancreatic, colorectal, breast, or lung cancer who are doing well on the treatment. The main goal is to safely provide continued access to the medication while monitoring for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Instytut Hematologii I Transfuzjologii
Warsaw, 02-776, Poland
-
New York Oncology Hematology Pc.
Clifton Park, New York, 12065, United States
-
Renovatio Clinical Consultants Llc
The Woodlands, Texas, 77380, United States
-
Samodzielny Publiczny Szpital Kliniczny
Lublin, 20-081, Poland
-
Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii
Krakow, 31-501, Poland
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
UCLA Healthcare Hematology-Oncology
Santa Monica, California, 90404, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.